biotech.today

Details

  • ●Modalities: small molecules
  • ●Therapeutic areas: oncology, immunology
  • ●Key targets:
  • ●Indications: Undisclosed
  • ●Funding: $30M

Partners & investors

  • Kurma Partners· Investor
  • Petri Bio· Investor
  • Sanofi· Investor

Key considerations

  • ●AI tools in use: Aqemia Platform
  • ●$30M Series A (2022)
  • ●Sanofi partnership (worth up to €140M)
  • ●Kurma Partners + Petri Bio / YC-backed
Get live updates on Aqemia’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Maximilien Levesque

Co-Founder & CEO

statistical-physicschemistry
Visit website →LinkedIn →